newsAntibody-immunotherapy treatment shows benefit in serious endometrial cancer5 April 2024 | By Catherine Eckford (European Pharmaceutical Review)The novel combination cancer therapy facilitated “exceptional” responses in some patients enrolled in a Phase II study for endometrial cancer.
newsAbbVie announces its new CEO23 February 2024 | By Catherine Eckford (European Pharmaceutical Review)During his tenure as AbbVie’s CEO, Richard Gonzalez successfully navigated the end of exclusivity for the biologic Humira in the US.
newsAbbVie agrees $10 billion oncology acquisition1 December 2023 | By Catherine Eckford (European Pharmaceutical Review)Under its proposed acquisition of ImmunoGen, AbbVie will gain rights to ELAHERE®, the first antibody-drug conjugate (ADC) approved in ovarian cancer.
articleAccelerating drug development22 February 2023 | By Dave Elder (David P Elder Constultancy)Here, Dave Elder explores how a ‘quick-approval, quick-withdrawal from the market’ approach is used to accelerate drug development.
newsImmunoGen and Merck collaborate for ovarian cancer trial5 February 2016 | By Victoria WhiteThe companies are to are to assess ImmunoGen’s mirvetuximab soravtansine in combination with Merck’s Keytruda (pembrolizumab) in FRα-positive ovarian cancer...
